Medical device company Kypha has raised $2.1 million in a debt offering to further it’s work in managing inflammation. With just one drop of blood, Kypha’s test works much like a diabetes test. Within just a few minutes, the test assigns a numeric value to indicate a potential condition.
At the point of care, physicians using this test would be able to make more effective decisions, especially with those suffering from diseases like Lupus, where inflammation is a mandatory thing to monitor.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Kypha has previously raised $6 million for development along with $1.5 million in grants. BioGenerator has been a prominent investor in the company, along with Arsenal Capital Management, and Serra Ventures from Champaign, Illinois; Saint Louis University’s Billiken Angels Network; St. Louis Arch Angels; and Holton Capital Group.